LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.07 1.9

Buy Sell

Overview

Share price change

24h

Current

Min

1.03

Max

1.1

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+362.96% upside

Market Stats
By TradingEconomics
Market Cap	-6.9M 119M
Previous open	-0.83
Previous close	1.07

News Sentiment

By Acuity

72%

28%

339 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

8 gru 2025, 23:48 UTC

Major Market Movers

Shares of Sezzle and Vital Farms Rise on S&P SmallCap 600 Inclusion

8 gru 2025, 23:44 UTC

Market Talk

Perky Australian Dollar Looks to Extend Gains -- Market Talk

8 gru 2025, 23:42 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Econ, Earnings -- Market Talk

8 gru 2025, 23:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 gru 2025, 23:13 UTC

Market Talk

Australian Inflation Expectations Highest Since Late 2023 -- Market Talk

8 gru 2025, 23:09 UTC

Acquisitions, Mergers, Takeovers

Paramount Made a Hostile Bid for Warner After Netflix Deal. What Happens Next? -- WSJ

8 gru 2025, 22:46 UTC

Market Talk

Rio Tinto Building Low-Cost Lithium Business in Difficult Market -- Market Talk

8 gru 2025, 22:01 UTC

Market Talk

Miners Poised to Do Well in 2026 -- Market Talk

8 gru 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

Noble: Agreement With Borr Includes Sale of Noble Tom Prosser, Noble Mick O'Brien, Noble Regina Allen, Noble Resilient, Noble Resolute, Closing Expected in Early 2026 >NE

8 gru 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

Noble: Agreement With Borr Comprises $210M in Cash and $150M in Seller Notes >NE

8 gru 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

Noble: Agreement With Ocean Oilfield Drilling Anticipates the Sale of the Noble Resolve, Closing Is Expected in 2Q 2026, Upon Conclusion of Noble Resolve's Current Contract >NE

8 gru 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

Noble: To Sell Five Rigs to Borr Drilling Limited for $360M and One Rig to Ocean Oilfield Drilling for $64M in Cash >NE

8 gru 2025, 21:51 UTC

Market Talk

US-Canada Rate Spreads Narrow Sharply After Record Gap -- Market Talk

8 gru 2025, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

8 gru 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 gru 2025, 21:38 UTC

Acquisitions, Mergers, Takeovers

Boeing Buys Company Responsible for Door Blowout. The Stock Rises. -- Barrons.com

8 gru 2025, 21:38 UTC

Acquisitions, Mergers, Takeovers

Paramount Makes $77.9 Billion Hostile Bid for Warner After Netflix Struck Deal -- 7th Update

8 gru 2025, 21:36 UTC

Market Talk

Oil Oversupply to Show Up As Waterborne Stocks Land -- Market Talk

8 gru 2025, 21:20 UTC

Acquisitions, Mergers, Takeovers

Will the Netflix-Warner Bros. Merger Go Through? It Depends on How You Define Market Share. -- Barrons.com

8 gru 2025, 21:12 UTC

Acquisitions, Mergers, Takeovers

These Stocks Moved the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8 gru 2025, 21:08 UTC

Market Talk

Rosenberg Turns 'Outright Bullish' on Canada Dollar -- Market Talk

8 gru 2025, 20:38 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Netflix Co-CEOs Confident About Regulatory Approval for WBD Deal -- Market Talk

8 gru 2025, 20:26 UTC

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

8 gru 2025, 20:18 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Netflix Isn't Looking to Make Cuts at Warner Bros. Discovery -- Market Talk

8 gru 2025, 20:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

8 gru 2025, 20:06 UTC

Market Talk

U.S. Natural Gas Pulls Back From Weather-Driven Highs -- Market Talk

8 gru 2025, 20:05 UTC

Market Talk

Global Equities Roundup: Market Talk

8 gru 2025, 20:05 UTC

Market Talk

Deere Offers Sales Growth Forecast Through 2030 -- Market Talk

8 gru 2025, 20:01 UTC

Market Talk

Precious Metals Slip Ahead of Fed Decision -- Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

362.96% upside

12 Months Forecast

Average 5 USD 362.96%

High 8 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

339 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.